Share

Prof. Pierantonio Menna

Biography

Prof. Pierantonio Menna is an Italian clinical pharmacologist. He graduated in Pharmaceutical Chemistry and Technology in 1999 from the University of Chieti-Pescara, where he received his PhD in Aging Sciences. He subsequently completed a postdoctoral training period at the Center of Excellence in Aging Research (CESI) at the University of Chieti and, between 2004 and 2005, he held a Research Fellowship at the Cancer Pharmacology Center – Mass Spectrometry Unit of the University of Pennsylvania School of Medicine in Philadelphia. In 2015, he specialized in Medical Pharmacology at the University of Rome “La Sapienza”. In 2007, he joined theUniversità Campus Bio-Medico di RomaHe was a pharmacologist member of the Ethics Committee of the Campus Bio-Medico University in the period 2019-2022. Since June 2021 he has held the role of Associate Professor of Pharmacology at the Departmental Faculty of Sciences and Bio-Technologies of theUniversità Campus Bio-Medico di RomaIn 2025, he obtained the National Scientific Qualification for the role of Full Professor in the 05/G1 Competitive Sector - Pharmacology, Clinical Pharmacology, and Pharmacognosy. He is currently Deputy Director of the School of Specialization in Pharmacology and Clinical Toxicology at the same university. His research and clinical activity focuses primarily on pharmacokinetics, pharmacodynamics, and pharmacogenetics, with a strong focus on precision medicine. He is the author of over seventy scientific publications indexed in PubMed, as well as numerous book chapters and presentations at national and international conferences.

Curriculum

"PRE-UNIVERSITY AND UNIVERSITY EDUCATION
-1994. Diploma in Industrial Chemistry
-1994-1999. Master's Degree in Pharmaceutical Chemistry and Technology, University "G. d'Annunzio", Chieti-Pescara
POST-GRADUATE EDUCATION
- 2025. Specialization Course in Healthcare Management, Università Campus Bio-Medico di Roma.
- 2015. Specialization in Medical Pharmacology, Sapienza University of Rome.
- 2005. PhD in “Aging Sciences”, University “G. d'Annunzio” of Chieti.
POST-GRADUATE PROFESSIONAL EXPERIENCE ABROAD
- 2004-2005. Visiting Scientist, University of Pennsylvania, Department of Pharmacology and Cancer Center, Philadelphia, PA.
ACADEMIC CAREER
- 2025. National Scientific Qualification for the role of Full Professor of University Sciences in the Competitive Sector 05/G1 - Pharmacology, Clinical Pharmacology and Pharmacognosy.
- 2021. Winner of the selection procedure for the filling of 1 position of Associate Professor in Pharmacology, Clinical Pharmacology and Pharmacognosy by call, Faculty of Food Sciences and Human Nutrition - Campus Bio-medico University of Rome
TEACHING ACTIVITIES IN DEGREE COURSES
- 2021 – present. Professor of Pharmacology at the Departmental Faculty of Sciences and Biotechnology, formerly Science and Technologies for Sustainable Development and One Health, Università Campus Bio-Medico di Roma.
- 2017 – 2021. Professor of Pharmacology, for the Master's Degree in Food Sciences and Human Nutrition, Università Campus Bio-Medico di Roma.
ASSISTANCE ACTIVITY
- Since 2009, Head of Quality Management System of the Pharmaco-Toxicology Laboratory - Clinical Pharmacology Unit - Fondazione Policlinico Universitario Campus Bio-Medico di Roma
- Since 2009, Head of the "Pharmaco-Toxicology Laboratory for Healthcare", Clinical Pharmacology Unit - Fondazione Policlinico Universitario Campus Bio-Medico di Roma
OTHER ACTIVITIES'
- 2026 – present. Pharmacologist for the Lazio-LLC Working Group (L-LLC).
- 2022 – present. Pharmacologist for SEIFEM (Italian Group for the Epidemiological Surveillance of Infections in Hematology)
- 2022. Expert Pharmacologist for “European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)”
- 2014 – 2015. Audit for Phase I studies system qualification (Dr. Marina Filippoauditor, QA ACRAF SpA, Aziende Chimiche Riunite Angelini Francesco).
- 2013. Audit for Phase I Studies System Qualification (Auditor, Dr. Paola Caponecchia auditor, QA Harrison International).
- 2009 – present. Head of the Pharmaceutical Area and Member of the ""QUALITY TEAM"" of the Departmental Faculty of Medicine and Surgery Università Campus Bio-Medico di Roma.
RESEARCH LINES
- Cardiac metabolism of anticancer anthracyclines and cardiotoxicity: Structure-activity studies in translational models of human myocardium.
- Development of preclinical models for screening and studying the structure-activity relationships of the cardiotoxicity of new anticancer drugs.
- Pharmacokinetics of antifungals in haematological patients.
- Research, development, and validation of analytical methods applied to Therapeutic Drug Monitoring by mass spectrometry.
- Preclinical and clinical cardiovascular safety profile of tyrosine kinase inhibitors with antileukemic activity.
- Quality systems in Phase I studies
- Management and analysis of biological samples in prospective, controlled and real-life studies."

PUBLICATIONS

"1. Tedeschi A, Frustaci AM, Menna P, Minotti G. Correspondence on Mauro et al.: ensuring meaningful conclusions through data accuracy and consistency.
Leukemia. 2026 Jul 17. Online ahead of print.
2. Camilli M, Madaudo C, Salvatorelli E, Minotti G and Menna P. Bruton Tyrosine Kinase Inhibitors and Cardiovascular Adverse Events.
British Journal of Pharmacology. 2026 Jul 8. Online ahead of print.
3. Roncato R, Perfler S, Gambron M, et al. Pharmacogenetic testing in Italy: results of a nationwide survey by the Joint Working Group for the pharmacogenetics implementation in Italy.
Eur J Hum Genet. 2026 Apr 3. Online ahead of print.
4. Salmanton-García J, Marchesi F, Cornely OA, Stemler J, and Menna P. Optimizing Treatment, Minimizing Risk: Therapeutic Drug Monitoring in Hematological Malignancies.
Mediterranean Journal of Hematology and Infectious Diseases. 2026; 18(1):e2026022.
5. Cusato J, Cafaro A, Cairoli S, Cangemi G, Cattaneo D, Di Paolo A, Menna P, Simeoli R, Tempestilli M, Goffredo BM. Indications for the harmonization of therapeutic intervals for antifungal drugs.
Clinical Biochemistry 2026;50:57-67
6. Tedeschi A, Frustaci AM, Menna P, and Minotti G. Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.
Leukemia 2025;39:2618–2621
7. Roberta Esposito, Pierantonio Menna, Emanuela Salvatorelli, Massimiliano Camilli, and Giorgio Minotti. On the adjudication of adverse cardiovascular events of ibrutinib in the patient with chronic lymphocytic leukemia: deaths in glow or blows in the wind?
Eur Cardiol. 2025;29:20:e27
8. G Assenza, B Sancetta, L Ricci, C Vico, F Narducci, M Boscarino, J Lanzone, P Menna, C Liguori, F Izzi, NB Mercuri, V Di Lazzaro , M Tombini. Cenobamate modulates EEG cortical activity and connectivity in individuals with drug-resistant epilepsy: a pharmaco-EEG study.
Front Neurol. 2025; 03:15 pm02668
9. Giorgio Minotti, Massimiliano Camilli, Emanuela Salvatorelli and Pierantonio Menna. Advances in BTK inhibition are steered by BTK phylogeny.
British Journal of Pharmacology 2025;182:1446-1451
10. Menna P, Salvatorelli E. Humans and Rodents: The Case of hOAT4 and mOat5.
J Pharmacol Exp Ther. 2024;39:375-377
11. Camilli M, Ferdinandy P, Salvatorelli E, Menna P, Minotti G. Anthracyclines, Diastolic Dysfunction and the road to Heart Failure in Cancer survivors: An untold story.
Prog Cardiovas Dis. 2024;86:38-47
12. Molteni L, Charlier B, Coglianese A, Izzo V, Assenza G, Menna P, de Grazia U, D'Urso A. Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry
Molecules 2024;29:884"

Roles in the University

QUICK LINKS
[] magnifiercrossmenuchevron-downchevron-leftchevron-right